Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients: LIKELIHOOD OF LY2603618 TO INHIBIT CYP2D6 IN CANCER PATIENTS
Biopharmaceutics & Drug Disposition（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要